Intra-Cellular Therapies, Inc. ITCI
Set alert
131.87 0.00 0.00%
At close · Apr 2
131.87 Day range 131.87
52-week range unavailable
- YTD
- +57.89%
- 1 year
- +97.80%
- Open
- 131.87
- Prev close
- 131.87
- Mkt cap
- 14.05B
- Vol
- 16.04M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 131.87
- High
- 131.87
- Forward P/E
- 507.19
- Beta
- 0.46
- Short ratio
- 1.20
- Inst. own
- 96.45%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 129.34
- 200-d avg
- 93.12
- 1y target
- 132.00
Analyst view
Consensus: hold
Hold
Price target (mean) 132.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 12
- 2 months ago 13
- 3 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.10 | -0.16 – -0.04 | -0.16 | +37.5% | 205.61M | +41.9% | 4 |
| Next quarter | 0.015 | -0.07 – 0.11 | -0.16 | +109.4% | 225.73M | +39.9% | 4 |
| Current year | 0.15 | -0.38 – 0.83 | -0.72 | +120.8% | 959.34M | +40.9% | 5 |
| Next year | 3.13 | 0.87 – 5.36 | 0.15 | +1984.1% | 1.42B | +47.8% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2, 2025 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Feb 24, 2025 | Mizuho | Downgrade | Outperform | Neutral |
| Feb 21, 2025 | Needham | Reiterated | Hold | Hold |
| Jan 31, 2025 | Canaccord Genuity | Downgrade | Buy | Hold |
| Jan 22, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Jan 14, 2025 | Piper Sandler | Downgrade | Overweight | Neutral |
| Jan 13, 2025 | Needham | Downgrade | Buy | Hold |
| Nov 4, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 31, 2024 | Needham | Reiterated | Buy | Buy |
| Oct 30, 2024 | Needham | Reiterated | Buy | Buy |
| Oct 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 4, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 20, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 16, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 6, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| Aug 21, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 8, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 8, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 8, 2024 | UBS | Maintained | Neutral | Neutral |
| Aug 8, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Aug 8, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 7, 2024 | Needham | Reiterated | Buy | Buy |
| Jul 22, 2024 | Needham | Maintained | Buy | Buy |
| Jun 25, 2024 | UBS | Downgrade | Buy | Neutral |
| Jun 25, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 21, 2024 | Mizuho | Maintained | Buy | Buy |
| Jun 20, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 18, 2024 | Needham | Maintained | Buy | Buy |
| Jun 14, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 12, 2024 | JP Morgan | Maintained | Overweight | Overweight |